title: Therapeutic safety and effects of adjuvant autologous RetroNectin activated killer cell immunotherapy for patients with primary hepatocellular carcinoma after radiofrequency ablation.
abstract: Hepatocellular carcinoma (HCC) recurs frequently after minimally invasive therapy. Adoptive immunotherapy is considered helpful in lowering recurrence and metastasis rates of malignant tumors. In this study, we report the combination of radiofrequency ablation (RFA) and autologous RetroNectin activated killer (RAK) cells in the treatment of HCC patients with a tumor size less than 4 cm. Autologous RAK cells were transfused via an intravenous drip into the patients. Flow cytometry was used to assess the change of percentages of lymphocyte subsets in the peripheral blood of the patients. Computed tomography was used to observe the tumor recurrent conditions of patients by every 2 m. During a seven-month follow-up, no severe adverse events, recurrences or deaths were observed in all 7 HCC patients. These preliminary results suggest the feasability and safety of the combined therapeutic regimen for HCC, and that the RAK cell adoptive immunotherapy might be helpful in preventing recurrence in HCC patients after RFA.
authors.affiliation: State Key Laboratory of Oncology in Southern China and Department of Experimental Research, Sun Yat-sen University Cancer Center, Yuexiu District, Guangzhou, Guangdong, China.
authors.forename: Haiqing
authors.initials: H
authors.lastname: Ma
authors.forename: Yaojun
authors.initials: Y
authors.lastname: Zhang
authors.forename: Qijing
authors.initials: Q
authors.lastname: Wang
authors.forename: Yongqiang
authors.initials: Y
authors.lastname: Li
authors.forename: Jia
authors.initials: J
authors.lastname: He
authors.forename: Hui
authors.initials: H
authors.lastname: Wang
authors.forename: Jiancong
authors.initials: J
authors.lastname: Sun
authors.forename: Ke
authors.initials: K
authors.lastname: Pan
authors.forename: Minshan
authors.initials: M
authors.lastname: Chen
authors.forename: Jianchuan
authors.initials: J
authors.lastname: Xia
mesh_terms: D000328:Adult; D015703:Antigens, CD / Q000378:metabolism; D006528:Carcinoma, Hepatocellular / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D017115:Catheter Ablation; D045744:Cell Line, Tumor; D002478:Cells, Cultured; D003131:Combined Modality Therapy; D003601:Cytotoxicity Tests, Immunologic; D003602:Cytotoxicity, Immunologic / Q000276:immunology; D005260:Female; D005353:Fibronectins / Q000276:immunology; D056945:Hep G2 Cells; D006801:Humans; D016130:Immunophenotyping; D016219:Immunotherapy, Adoptive / Q000379:methods*; D007371:Interferon-gamma / Q000378:metabolism; D007694:Killer Cells, Natural / Q000166:cytology / Q000276:immunology / Q000637:transplantation*; D008113:Liver Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D008213:Lymphocyte Activation / Q000276:immunology; D008214:Lymphocytes / Q000276:immunology / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000276:immunology
chemical_list: D015703:Antigens, CD; D005353:Fibronectins; D011994:Recombinant Proteins; C545354:retronectin; D007371:Interferon-gamma